Bayer's Second-Quarter Turnaround Meets a Delayed Courtroom Reckoning
Published on 08/14/2026 at 14:02 | Redaktion boerse-global.de
The numbers that Bayer delivered on August 4 told a story of operational resilience, but the calendar that governs its most consequential legal battle keeps shifting. The German conglomerate swung back to profitability in the second quarter of 2026, posting net income of €219 million against a €199 million loss in the same period a year earlier — a swing that caught most analysts off guard.
Group revenue reached €10.872 billion, up 2.2 percent on a currency- and portfolio-adjusted basis, while adjusted EBITDA advanced 1.9 percent to €2.144 billion. That EBITDA figure carried particular weight: market consensus had penciled in a decline of roughly 8 percent. Management used the occasion to reaffirm its full-year guidance.
Crop Science Carries the Quarter
The agricultural division delivered the strongest performance, with currency- and portfolio-adjusted sales climbing 3.5 percent to €4.910 billion. Adjusted segment earnings jumped 30.2 percent, helped by higher prices and lower manufacturing costs. Cottonseed was the standout, surging 69.2 percent after the Dicamba label returned to the US market, while soybean seed and traits added 16.9 percent.
Pharma, by contrast, treaded water — sales flat year-on-year and earnings down. The oncology drug Nubeqa continued to show momentum as a growth driver, though the precise quarterly contribution wasn't broken out in the available disclosures. Consumer Health managed only modest top-line growth.
The headline profit figure masked a weaker per-share metric. Core earnings per share fell 16.7 percent to €0.95, which Bayer attributed to a normalized tax rate and lower results in the reconciliation segment — only partially offset by the Crop Science improvement.
Cash Flow and Debt: The Lingering Pressure Points
Free cash flow turned negative at minus €371 million, versus plus €125 million a year earlier, with higher litigation settlement payments doing much of the damage. Net financial debt stood at €33.647 billion as of June 30 — above the company's original full-year target of €32 to €33 billion.
Yet management now sounds more confident about deleveraging than it did in the spring. Bayer has revised its year-end debt outlook down to a range of €29 to €30 billion. Supporting that ambition, the company reportedly arranged a new billion-euro refinancing credit facility aimed specifically at strengthening the agriculture business.
Bayer also tapped the dollar bond market in mid-July, raising $5 billion across five tranches with maturities spanning five to thirty years. Market reports indicated the offering was multiple times oversubscribed.
The Glyphosate Hearing Slips Again
The legal calendar remains the dominant overhang. The US Supreme Court ruled in late June in Monsanto v. Durnell by a 7-2 margin that federal EPA labeling requirements preempt stricter state-level warning obligations — a decision that undermines the core legal theory behind Roundup claims.
The proposed multibillion-dollar class settlement, designed to cover current and future claims over roughly 21 years with a value of up to $7.25 billion, was originally scheduled for a court hearing on August 19. That hearing has now been pushed to September 14. The delay gives the parties and the settlement administrator additional time to process withdrawal requests from plaintiffs who may want to exit the deal in light of the Supreme Court ruling.
While Bayer navigates its legal uncertainties, UK employers face their own compliance risks — often without realizing where their documentation falls short. A free Health & Safety Toolkit provides ready-to-use risk assessments and checklists that cover key regulations like the Health & Safety at Work Act 1974 and COSHH. Download the free Health & Safety Toolkit
Analyst Reactions and the Share Price Picture
Wall Street's response to the quarterly figures was largely constructive. JPMorgan reaffirmed its "Overweight" rating on August 5, with Goldman Sachs, Deutsche Bank, and UBS all maintaining "Buy" calls. Jefferies' Michael Leuchten struck a more cautious tone, reiterating "Hold" with a €46 price target on August 10.
The stock's trajectory reflects that mixed sentiment. Shares closed Thursday at €47.99, down 3.8 percent on the week — a pullback that followed a 4.5 percent decline in the prior week as investors weighed the delayed hearing. The stock remains roughly 11 percent below its 52-week high of €53.86, reached in early July, but sits comfortably above its 200-day moving average of €40.28. The recovery from November's low of €25.78 has been dramatic: a 30 percent gain year-to-date and roughly 80 percent over twelve months.
Near-term volatility, however, remains elevated, with annualized 30-day volatility running at 26 percent. The next major catalyst arrives November 10, when Bayer is scheduled to report third-quarter results — by which point the September 14 hearing will have clarified whether the settlement path remains viable or faces further fragmentation.
Just as Bayer's legal exposure hinges on regulatory compliance, your business's liability can hinge on how well you document workplace hazards. Over 37,000 UK companies already use a free toolkit with 41 ready-made templates and checklists for fire safety, manual handling, first aid and lone working — everything you need to stay compliant. Get the free Risk Assessment Toolkit
